The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11033 malaria professionals are enjoying the free benefits of MalariaWorld today

pre-erythrocytic vaccine

Not Open Access | Plasmodium pre-erythrocytic vaccine antigens enhance sterile protection in mice induced by circumsporozoite protein

July 28, 2021 - 14:28 -- NOT Open Access
Author(s): 
Daniel S, Pichugin A, Duffy PE, et al.
Reference: 
Infect Immun. 2021 Jul 26:IAI0016521

Pre-erythrocytic vaccines prevent malaria by targeting parasites in the clinically silent sporozoite and liver stages and preventing progression to the virulent blood stages. The leading pre-erythrocytic vaccine RTS,S/AS01E (Mosquirix®) entered implementation programs in 2019 and targets the major sporozoite surface antigen called circumsporozoite protein or CSP.

Plasmodium vivax pre-erythrocytic vaccines

June 30, 2021 - 12:55 -- Open Access
Author(s): 
Reyes-Sandoval A
Reference: 
Parasitol Int. 2021 Jun 21;84:102411

An estimated 229 million cases of malaria occurred worldwide in 2019. Both, Plasmodium falciparum and P. vivax are responsible for most of the malaria disease burden in the world. Despite difficulties in obtaining an accurate number, the global estimates of cases in 2019 are approximately 229 million of which 2.8% are due to P. vivax, and the total number of malaria deaths are approximately 409 million.

Subscribe to RSS - pre-erythrocytic vaccine